Page 74 - Read Online

Shad. J Transl Genet Genom 2023;7:141-65 https://dx.doi.org/10.20517/jtgg.2023.11 Page 163

and association with allelic variants of multidrug resistance gene MDR1. J Clin Psychopharmacol 2011;31:247-9. DOI PubMed
116. Osafo-Addo AD, Koram KA, Oduro AR, Wilson M, Hodgson A, Rogers WO. HLA-DRB1*04 allele is associated with severe
malaria in northern Ghana. Am J Trop Med Hyg 2008;78:251-5. PubMed
117. Park HW, Kim DK, Kim SH, et al. Efficacy of the HLA-B*58:01 screening test in preventing allopurinol-induced severe cutaneous
adverse reactions in patients with chronic renal insufficiency-a prospective study. J Allergy Clin Immunol Pract 2019;7:1271-6. DOI
118. Wang Q, Sun S, Xie M, Zhao K, Li X, Zhao Z. Association between the HLA-B alleles and carbamazepine-induced SJS/TEN: a
meta-analysis. Epilepsy Res 2017;135:19-28. DOI
119. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in
some, but not all, populations. Pharmacogenomics 2004;5:203-11. DOI
120. Capule F, Tragulpiankit P, Mahasirimongkol S, et al. Association of carbamazepine-induced Stevens-Johnson syndrome/toxic
epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients. Pharmacogenomics J 2020;20:533-41.
DOI
121. Verbelen M, Collier DA, Cohen D, MacCabe JH, Lewis CM. Establishing the characteristics of an effective pharmacogenetic test for
clozapine-induced agranulocytosis. Pharmacogenomics J 2015;15:461-6. DOI PubMed PMC
122. Grover S, Kukreti R. HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis.
Pharmacogenet Genomics 2014;24:94-112. DOI PubMed
123. Mijovic A, MacCabe JH. Clozapine-induced agranulocytosis. Ann Hematol 2020;99:2477-82. DOI PubMed PMC
124. Konte B, Walters JTR, Rujescu D, et al. HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and
agranulocytosis in individuals of European ancestry. Transl Psychiatry 2021;11:214. DOI PubMed PMC
125. Saito T, Ikeda M, Hashimoto R, et al. Transethnic replication study to assess the association between clozapine-induced
agranulocytosis/granulocytopenia and genes at 12p12.2 in a Japanese population. Biol Psychiatry 2017;82:9-e10. DOI
126. Chen J, Yang P, Zhang Q, et al. Genetic risk of clozapine-induced leukopenia and neutropenia: a genome-wide association study.
Transl Psychiatry 2021;11:343. DOI PubMed PMC
127. Mosyagin I, Dettling M, Roots I, Mueller-Oerlinghausen B, Cascorbi I. Impact of myeloperoxidase and NADPH-oxidase
polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol 2004;24:613-7. DOI PubMed
128. Legge SE, Pardiñas AF, Helthuis M, et al. A genome-wide association study in individuals of African ancestry reveals the importance
of the Duffy-null genotype in the assessment of clozapine-related neutropenia. Mol Psychiatry 2019;24:328-37. DOI
129. Okhuijsen-Pfeifer C, Sterk AY, Horn IM, Terstappen J, Kahn RS, Luykx JJ. Demographic and clinical features as predictors of
clozapine response in patients with schizophrenia spectrum disorders: A systematic review and meta-analysis. Neurosci Biobehav Rev
2020;111:246-52. DOI PubMed
130. Comacchio C, Dusi N, Lasalvia A. Successful use of single doses of granulocyte-colony stimulating factor (G-CSF) in the treatment
of late-onset agranulocytosis associated with clozapine in a patient with treatment-resistant schizophrenia: a case report. J Clin
Psychopharmacol 2016;36:173-4. DOI
131. Freeman GM Jr, Martin BA, Hu RJ. G-CSF dosing to prevent recurrent clozapine-induced agranulocytosis. Am J Psychiatry
2016;173:643. DOI PubMed
132. Lally J, Malik S, Krivoy A, et al. The use of granulocyte colony-stimulating factor in clozapine rechallenge: a systematic review. J
Clin Psychopharmacol 2017;37:600-4. DOI
133. Blier P, Slater S, Measham T, Koch M, Wiviott G. Lithium and clozapine-induced neutropenia/agranulocytosis. Int Clin
Psychopharmacol 1998;13:137-40. DOI PubMed
134. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol
Psychiatry 2007;12:707-47. DOI PubMed
135. Shad MU. Clozapine toxicity: a discussion of pharmacokinetic factors. Asian J Psychiatr 2008;1:47-9. DOI PubMed
136. Shad MU, Felzien E, Roy K, Sethi S. How to identify and manage non-response to clozapine? Asian J Psychiatr 2019;45:50-2. DOI
PubMed
137. Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and
relevance for drug-drug interactions. Curr Drug Metab 2008;9:410-8. DOI PubMed
138. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm 2007;64:1917-21. DOI PubMed
139. Rajkumar AP, Poonkuzhali B, Kuruvilla A, Srivastava A, Jacob M, Jacob KS. Association between CYP1A2 gene single nucleotide
polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia. Acta Neuropsychiatr 2013;25:2-
11. DOI PubMed
140. Piatkov I, Caetano D, Assur Y, et al. ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine.
Pharmgenomics Pers Med 2017;10:235-42. DOI PubMed PMC
141. Xing Q, Gao R, Li H, et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese
schizophrenia patients. Pharmacogenomics 2006;7:987-93. DOI
142. Zhao AL, Zhao JP, Zhang YH, Xue ZM, Chen JD, Chen XG. Dopamine D4 receptor gene exon III polymorphism and interindividual
variation in response to clozapine. Int J Neurosci 2005;115:1539-47. DOI PubMed
143. Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-
analysis. Am J Psychiatry 2010;167:763-72. DOI PubMed PMC
144. Gressier F, Porcelli S, Calati R, Serretti A. Pharmacogenetics of clozapine response and induced weight gain: a comprehensive